Cryptogenic Ischemic Stroke

SAN FRANCISCO--( BUSINESS WIRE )--First paragraph, second sentence of release should read: Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage. (instead of: Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage.). The updated release reads: VIZ.AI ANNOUNCES SIX CLINICAL STUDIES THAT FURTHER VALIDATE IMPACT OF VIZ ™ NEURO SUITE ON PATIENT CARE Real-world evidence presented at the 2024 International Stroke Conference shows positive impact on clinical workflow and patient benefits of AI-powered care coordination Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage. “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs. “Our commitment to neurology care teams and the patients who benefit from early intervention is a core value at Viz.ai, when we say ‘patients first,’ we mean it.” Abstracts accepted for presentation at ISC: “Artificial Intelligence Algorithm as a Diagnostic Tool for Aneurysms” evaluated the performance of the Viz Aneurysm algorithm. The study found that across 963 retrospectively-collected head computed tomography (CT) scans, Viz Aneurysm demonstrated a specificity of 96.8% and a negative predictive value of 97.2%. “Our findings show that Viz Aneurysm is a highly specific tool that can help to identify aneurysms,” said Justin Fraser, MD, FAANS, FAHA, Vice-Chair and Director of Cerebrovascular and Endovascular Surgery in the Department of Neurological Surgery, University of Kentucky. “The integration of AI technology into our aneurysm workflow helps us to promptly evaluate and triage these potentially unstable patients.” “User Engagement is Associated with Clinical Impacts of Automated LVO Detection Software” was a post-hoc analysis of the multicenter, prospective, randomized clinical trial. The analysis found an 11-minute reduction in door to groin (DTG) time across all centers with Viz LVO implementation. This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement. “Accurate and early detection of stroke using Viz LVO significantly improved our door to groin time,” said Sunil Sheth, MD, Director of Vascular and Interventional neurology, Associate Professor of Neurology, UTHealth McGovern Medical School. “These findings provide confirmation of the importance of end user engagement and interaction when using ML-based acute ischemic stroke large vessel occlusion detection.” “Estimation of Ventricular and Intracranial Hemorrhage Volumes and Midline Shift on an External Validation Data Set Using a Convolutional Neural Network Algorithm” evaluated the performance of a convolutional neural network (CNN), Viz ICH+, to automatically quantify intracranial hemorrhage (ICH) and lateral ventricular (LV) volumes as well as midline shift (MLS) compared to the more time intensive, manual neuroradiologists segmentation. The described CNN performed exceptionally well at quantifying ICH, LV volumes, and MLS with satisfying agreement on trend analysis in an independent validation imaging set. “Impact of Artificial Intelligence on Acute Ischemic Stroke Treatment in a Large Academic Healthcare System” evaluated the impact of the implementation of a stroke triage artificial intelligence software on a large academic healthcare system. In addition to reduction in time-to-treatment, results show a large reduction in unnecessary transfers (60 transfers) throughout the two-year study. “Door to Angiography in Large Vessel Occlusions Pre and Post Implementation of Automated Image Interpretation and Sharing Platform: A Single Center Study” showed that implementation of Viz LVO software was associated with shorter intervals between initial hospital contact and neurointervention among transferred patients. “Long-Term Cardiac Monitoring in Cryptogenic Stroke: The San Diego Experience” assessed the real-world reliability and experience of implantable cardiac monitors in two large, academic Comprehensive Stroke Centers. The study showed that long-term cardiac monitoring has been shown to detect significant rates of atrial fibrillation, especially in cryptogenic stroke. For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro . About Viz.ai, Inc. Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 230 million lives across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai® One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

SAN FRANCISCO--( BUSINESS WIRE )--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage. “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs. “Our commitment to neurology care teams and the patients who benefit from early intervention is a core value at Viz.ai, when we say ‘patients first,’ we mean it.” Abstracts accepted for presentation at ISC: “Artificial Intelligence Algorithm as a Diagnostic Tool for Aneurysms” evaluated the performance of the Viz Aneurysm algorithm. The study found that across 963 retrospectively-collected head computed tomography (CT) scans, Viz Aneurysm demonstrated a specificity of 96.8% and a negative predictive value of 97.2%. “Our findings show that Viz Aneurysm is a highly specific tool that can help to identify aneurysms,” said Justin Fraser, MD, FAANS, FAHA, Vice-Chair and Director of Cerebrovascular and Endovascular Surgery in the Department of Neurological Surgery, University of Kentucky. “The integration of AI technology into our aneurysm workflow helps us to promptly evaluate and triage these potentially unstable patients.” “User Engagement is Associated with Clinical Impacts of Automated LVO Detection Software” was a post-hoc analysis of the multicenter, prospective, randomized clinical trial. The analysis found an 11-minute reduction in door to groin (DTG) time across all centers with Viz LVO implementation. This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement. “Accurate and early detection of stroke using Viz LVO significantly improved our door to groin time,” said Sunil Sheth, MD, Director of Vascular and Interventional neurology, Associate Professor of Neurology, UTHealth McGovern Medical School. “These findings provide confirmation of the importance of end user engagement and interaction when using ML-based acute ischemic stroke large vessel occlusion detection.” “Estimation of Ventricular and Intracranial Hemorrhage Volumes and Midline Shift on an External Validation Data Set Using a Convolutional Neural Network Algorithm” evaluated the performance of a convolutional neural network (CNN), Viz ICH+, to automatically quantify intracranial hemorrhage (ICH) and lateral ventricular (LV) volumes as well as midline shift (MLS) compared to the more time intensive, manual neuroradiologists segmentation. The described CNN performed exceptionally well at quantifying ICH, LV volumes, and MLS with satisfying agreement on trend analysis in an independent validation imaging set. “Impact of Artificial Intelligence on Acute Ischemic Stroke Treatment in a Large Academic Healthcare System” evaluated the impact of the implementation of a stroke triage artificial intelligence software on a large academic healthcare system. In addition to reduction in time-to-treatment, results show a large reduction in unnecessary transfers (60 transfers) throughout the two-year study. “Door to Angiography in Large Vessel Occlusions Pre and Post Implementation of Automated Image Interpretation and Sharing Platform: A Single Center Study” showed that implementation of Viz LVO software was associated with shorter intervals between initial hospital contact and neurointervention among transferred patients. “Long-Term Cardiac Monitoring in Cryptogenic Stroke: The San Diego Experience” assessed the real-world reliability and experience of implantable cardiac monitors (ICM) in two large, academic Comprehensive Stroke Centers (CSC). The study showed that long-term cardiac monitoring has been shown to detect significant rates of atrial fibrillation (AF), especially in cryptogenic stroke. For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro . About Viz.ai, Inc. Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 230 million lives across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai® One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Company provides advanced IoT Platform and wearable sensors to capture health vital signs for clinical trials and patient care. Investment between Niterra Co., Ltd. CVC Fund and Pegasus Tech Ventures supports technology detecting and assessing Cardiology, Oncology, Neurology, and Hypertension conditions Vivalink Medical, Inc. (CA, USA) technology has been installed in 45 countries worldwide, granted 20 patents, and utilized in 21 research institutions. The company is collaborating with 250+ commercial partners Investment enhances healthcare with clinical grade physiology metrics powered by wearable sensors, network data services, algorithms, and clinician portals SANTA CLARA, Calif., Nov. 9, 2023 /PRNewswire/ -- Niterra (formerly NGK Spark Plug Co. LTD, Headquarters: Higashi-Ku, Nagoya) provided a strategic joint-partnership investment through the CVC fund jointly operated with Pegasus Tech Ventures (Headquarters: CA, USA) to a remote patient monitoring services company, Vivalink Medical, Inc (Headquarters: CA, USA), that specializes in home healthcare, telemedicine, and wearable technology. Continue Reading Niterra is in charge of creating new revenue streams to realize the "2030 Long-Term Management Plan NITTOKU BX," which outlines the transformation of the business portfolio towards an increase of the ratio of businesses not related to the internal combustion engine. To achieve this, Niterra plans to promote the creation of new businesses in the areas of Healthcare, Energy and Environment, Mobility, and Communications. As part of Niterra's efforts in Healthcare, the company is developing and investing in innovative home health and point-of-care solutions as their long-term growth strategy. "Our vision at Niterra is to improve the quality of life for everybody," said Dirk Schapeler, President of Niterra. Post this "Our vision at Niterra is to improve the quality of life for everybody," said Dirk Schapeler, President of Niterra. "We partner with the best industry professionals and brightest entrepreneurs to develop remote patient monitoring platforms to serve advanced patient care at home and medical environments." Vivalink is a provider of digital healthcare solutions including biometrics for virtual patient care and decentralized clinical trials. They leverage unique physiology-optimized medical wearable sensors and related data services to enable a deeper and more clinical understanding between provider and patient. In addition, they have a track record of business operations in 45 countries around the world, FDA/CE/NMPA clearance, and are compliant with the Personal Information Data Protection Directive and related regulations (HIPAA, GDPR). Vivalink has delivered over a decade of health tech innovations and a broad array of successful milestones, which includes development of a first-of-its-kind when presented eSkin technology, launching a temperature monitor, launching a medical wearable sensor, FDA & CE Clearance of an ECG platform, and various clinical trials. "We are proud to have Niterra and Pegasus Tech Ventures as a key strategic investment partner to the Vivalink Team," said Jiang Li, Founder & Chief Executive Officer of Vivalink. "This investment allows Vivalink to accelerate the development of our platform and its commercial growth worldwide. Our shared vision is to help healthcare organizations and patients be successful with faster time to market, a regulatory cleared platform, lower development costs, and common infrastructure." Overview of Vivalink Remote Patient Monitoring (RPM) Vivalink's biometric platform accelerates the deployment of virtually any type of remote patient monitoring application for healthcare and clinical trials. Examples of these RPM applications include cardiac arrhythmia, cryptogenic stroke, cardiac rehab, COPD, neutropenia, and cytokine release syndrome. For more information and to learn how Vivalink Medical, Inc. can help your company, visit: About Niterra Global innovation and collaboration hub to improve quality of life worldwide Established in 2018 to combine all business creation activities in one global team using internal development, collaboration with external partners, and investment. Goal is to establish $1 billion in new revenue by 2030 Niterra is a global team with locations in Japan (Nagoya and Tokyo), Germany, and the U.S. For more information and to learn how Niterra Ventures can help your company, visit: About Pegasus Tech Ventures Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley, offering intellectual and financial capital to exceptional emerging technology companies around the world. In addition to a more traditional investment approach, Pegasus offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Our goal is to accelerate the success of our portfolio companies by connecting them to our network of multinational corporate partners to create opportunities for business development, manufacturing, distribution, and global expansion. Pegasus' global corporate network includes Global Fortune 500 companies and other reputable multinational corporations across a wide variety of industries, such as consumer electronics, automotive, original design manufacturing, gaming, systems integration, health, and pharmaceuticals. Pegasus Tech Ventures applies a collaborative approach to working with entrepreneurs and our limited partners. We help our portfolio companies grow quickly and achieve success on a global scale. For more information about Niterra's corporate venture capital fund with Pegasus Tech Ventures, see the announcement here: For more information and to learn how Pegasus Tech Ventures can help your company, visit: SOURCE Niterra